ad

Dr Agarwal's Analyst Review 2027: Record Revenue and 324 Centres as Motilal Oswal Eyes ₹620

18 Nov 2026 • 3:06 pm

Dr Agarwal's Analyst Review 2027: Record Revenue and 324 Centres as Motilal Oswal Eyes ₹620

Dr. Agarwal's Health Care Stock Snapshot (17 Nov 2026 close)

  • Current Market Price (CMP): ₹539.95
  • 52-Week High / Low: ₹571.90 / ₹401.00
  • Market Capitalisation: ₹17,114 crore
  • P/E Ratio vs Industry P/E: 83.3 vs 63.9
  • Latest Quarter (Q2 FY27) Revenue: ₹655 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹57 crore

Quick Answer: The Dr Agarwal's analyst review 2027 has one verified target: Motilal Oswal's Buy with ₹620 from August 2026, about 15% above the ₹539.95 close. Q2 FY27 revenue from operations rose about 31.4% to a record ₹655 crore and net profit rose to about ₹57 crore from ₹36.49 crore. The chain added 21 facilities in the quarter to reach 324. The stock trades near 83 times trailing earnings against an industry P/E of about 64, so the Dr Agarwal's share price target 2027 depends on new centres turning profitable quickly.

The Dr Agarwal's analyst review 2027 covers India's largest eye care hospital chain, which runs cataract, refractive and retina surgery centres across India and in parts of Africa. Investors searching for a Dr Agarwal's share price target 2027 will find one named brokerage figure that still sits above the current price.

Dr. Agarwal's Health Care closed at ₹539.95 on 17 November 2026. That is about 6% below its 52-week high of ₹571.90 and about 35% above its low of ₹401. This Dr Agarwal's analyst review 2027 sets out the brokerage view, the September quarter and the factors that will shape the Dr Agarwal's stock outlook 2027.

Click Here – Get Free Investment Predictions

What Brokerages Say in the Dr Agarwal's Analyst Review 2027

Brokerage Rating Target Price Date
Motilal Oswal Buy ₹620 August 2026, after Q1 FY27

Motilal Oswal set its ₹620 target after the June quarter results. The brokerage case rests on steady same-centre growth, a rising share of premium surgeries and a fast pace of network additions. The target implies about 15% upside from the 17 November close.

The September quarter supported that view with record revenue and higher profit. The Dr Agarwal's analyst review 2027 will be tested on whether that pace holds while dozens of new centres ramp up at the same time.

Q2 FY27 Results in the Dr Agarwal's Analyst Review 2027

Quarter Total Income EBITDA Net Profit
Sep 2026 (Q2 FY27) ₹665.21 crore ₹185.56 crore ₹56.85 crore
Jun 2026 (Q1 FY27) ₹620.43 crore ₹176.82 crore ₹55.02 crore
Mar 2026 (Q4 FY26) ₹576.69 crore ₹174.05 crore ₹49.96 crore
Dec 2025 (Q3 FY26) ₹540.40 crore ₹154.64 crore ₹43.63 crore
Sep 2025 (Q2 FY26) ₹506.62 crore ₹144.07 crore ₹36.49 crore

Revenue from operations rose about 31.4% to ₹655 crore from ₹499 crore, the highest in the company's history. EBITDA rose about 29% to ₹185.56 crore. Net profit climbed about 56% to ₹56.85 crore, and profit has now risen for five straight quarters.

For the first half of FY27, revenue rose about 28.7% to ₹1,269.48 crore and profit rose about 50.1% to ₹111.87 crore. H1 EBITDA margin was about 28.2%. That steady climb is the core of the Dr Agarwal's analyst review 2027.

How Dr. Agarwal's Health Care Makes Money

The company earns most of its revenue from eye surgeries and consultations, with smaller income from optical products and pharmacy sales inside its centres.

  • Cataract surgery: the largest service line. High-end lens procedures now make up about 30% of cataract volumes, lifting revenue per surgery.
  • Refractive and retina: LASIK-type procedures and retina care carry higher prices.
  • Optical and pharmacy: spectacles, lenses and medicines sold at each facility.
  • Network: 324 facilities after 39 additions in H1 FY27, through new openings and acquisitions.

The merger with listed group company Dr. Agarwal's Eye Hospital is now effective, which simplifies the structure. Annual revenue rose from about ₹1,377 crore in FY24 to ₹1,757 crore in FY25 and ₹2,125 crore in FY26. Profit rose from ₹95 crore to ₹110 crore and then ₹168 crore. Operating cash flow reached about ₹519 crore in FY26, a strong point in the Dr Agarwal's analyst review 2027.

Growth Triggers in the Dr Agarwal's Analyst Review 2027

  • Network expansion: 21 new facilities in Q2 alone, taking the total to 324.
  • Premium mix: high-end surgeries at about 30% of cataract volumes lift average revenue.
  • Scale benefits: profit grew about 56% in Q2, faster than revenue at about 31%, as older centres mature.
  • Simpler structure: the completed merger removes the listed subsidiary.
  • Cash generation: FY26 operating cash flow of about ₹519 crore funds expansion, which backs the Dr Agarwal's share price target 2027 case.

Key Risks in the Dr Agarwal's Analyst Review 2027

  • Rich valuation: a P/E near 83 is well above the industry figure of about 64.
  • Low return on equity: about 8% as new centres and acquisitions take time to earn.
  • Expansion risk: adding 39 facilities in six months strains doctor hiring and margins.
  • Debt: debt to equity of about 0.53 includes lease liabilities on rented centres.
  • Foreign selling: FII holding fell from 58.13% to 49.56% over the year, a notable shift in the Dr Agarwal's analyst review 2027.

Compare Dr Agarwal's Health Care With Other Hospital Stocks on the Univest Screener

Dr Agarwal's Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (17 Nov 2026 close) ₹539.95
52-Week High / Low ₹571.90 / ₹401.00
Market Capitalisation ₹17,114 crore
P/E (TTM) vs Industry 83.3 vs 63.9
Price to Book 7.65
Book Value per Share ₹70.57
Return on Equity 8.04%
Debt to Equity 0.53
EPS (TTM) ₹6.48
FY26 Revenue / Net Profit ₹2,125 crore / ₹168 crore

Price to book value of about 7.65 and return on equity near 8% show that the market pays for future growth, not current returns. In the Dr Agarwal's analyst review 2027, the premium needs profit to keep growing near 50% a year. The BSE Healthcare index gives a sector benchmark.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 32.42% 32.33% Down 0.09 pts
Foreign Investors (FII) 58.13% 49.56% Down 8.57 pts
Domestic Institutions (DII) 7.92% 15.87% Up 7.95 pts
Public 1.52% 2.24% Up 0.72 pts

The Agarwal family promoter group holds about 32.3%. Foreign holders cut their stake by about 8.6 points. Domestic funds roughly doubled their holding to about 15.9%, absorbing that supply. The handover from foreign to domestic money is a key theme in the Dr Agarwal's analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Dr Agarwal's Analyst Review 2027

  • New centre ramp-up: how quickly the 39 facilities added in H1 reach break-even.
  • Margins: whether EBITDA margin holds near 28% as expansion continues.
  • Premium share: growth in high-end cataract and refractive procedures.
  • FII supply: any further stake sales by foreign holders.
  • Target revisions: a change to ₹620 after Q2 would reset the Dr Agarwal's share price target 2027.

Final Word on the Dr Agarwal's Analyst Review 2027

The Dr Agarwal's analyst review 2027 shows record revenue, five straight quarters of profit growth and a network that keeps expanding. Motilal Oswal's ₹620 target sits about 15% above the price, while the valuation already assumes strong growth.

The Dr Agarwal's stock outlook 2027 depends on how fast new centres mature, whether margins hold and how foreign stake sales play out. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Dr Agarwal's analyst review 2027 show?

It shows record revenue and steady profit growth. Q2 FY27 revenue from operations rose about 31.4% to ₹655 crore. Net profit rose about 56% to ₹56.85 crore. The network grew to 324 facilities.

What is the Dr Agarwal's share price target 2027 from brokerages?

Motilal Oswal has a Buy rating with a ₹620 target from August 2026. The stock closed at ₹539.95 on 17 November 2026. That implies about 15% upside.

How did Dr. Agarwal's Health Care perform in H1 FY27?

H1 FY27 revenue rose about 28.7% to ₹1,269.48 crore. Profit rose about 50.1% to ₹111.87 crore. H1 EBITDA margin was about 28.2%, and 39 facilities were added in the six months.

How does Dr. Agarwal's Health Care make money?

It earns mainly from cataract, refractive and retina surgeries and consultations. Optical and pharmacy sales add smaller income. High-end cataract procedures are about 30% of volumes. FY26 revenue was about ₹2,125 crore.

Is the stock expensive based on the Dr Agarwal's analyst review 2027?

The P/E of about 83 is above the industry figure of about 64. Price to book is about 7.65, while return on equity is about 8%. The valuation assumes profit keeps growing fast.

What risks does the Dr Agarwal's analyst review 2027 highlight?

The main risks are a rich valuation, low return on equity and rapid expansion. Foreign investors cut their stake from 58.13% to 49.56% over the year. Debt to equity is about 0.53, including leases.

What should investors track after the Dr Agarwal's analyst review 2027?

Track how quickly the 39 new facilities from H1 reach break-even. Watch whether EBITDA margin holds near 28%. Further foreign stake sales and any change to Motilal Oswal's ₹620 target also matter.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down